Monotherapy Pazopanib in Subjects With Advanced Non-Small Cell Lung Cancer
Status:
Terminated
Trial end date:
2009-04-01
Target enrollment:
Participant gender:
Summary
This study is designed to evaluate the efficacy and safety of monotherapy pazopanib (a small
molecule tyrosine kinase inhibitor of VEGFR-1, VEGFR-2, VEGFR-3, PDGF, and c-kit) in subjects
with advanced (Stage IIIB or IV) non-small cell lung cancer.